Stephen J.LurieMD, PhD, Senior EditorIndividualAuthorPhil B.FontanarosaMD, Executive Deputy EditorIndividualAuthor
To the Editor: The usefulness of genotype resistance
testing in the clinical management of HIV infection is increasingly clear.
However, as Dr Hirsch and colleagues1 state,
several technical issues concerning standardization and clinical validation
have yet to be resolved.
Although genotypic assays are increasingly common in the clinical setting,
interpretation of results is more complex than merely identifying mutations
and then eliminating antiretroviral drugs that supposedly are not efficacious.
In fact, the same combinations of primary and secondary mutations may result
from several different scenarios.
Pèrez-Molina JA, Fernández RA. The Role of Genotypic Resistance Testing in Selecting Therapy for HIV. JAMA. 2000;284(13):1649-1650. doi:10.1001/jama.284.13.1647